Dr. Ashani T. Weeraratna on Aging and its Effects on How Melanoma Progresses and is Treated
Ashani T. Weeraratna, PhD, discusses the similarities in treatment between younger and older patients with melanoma. She says this lack of differentiation between treatment regimens could pose a problem in the future. One such issue is that older patients tend to react less well to treatments like vemurafenib.
Ashani T. Weeraratna, PhD, associate professor, Tumor Microenvironment and Metastasis Program, The Wistar Institute, discusses the similarities in treatment between younger and older patients with melanoma. She says this lack of differentiation between treatment regimens could pose a problem in the future. One such issue is that older patients tend to react less well to treatments like vemurafenib.
Weeraratna says in order to better treat older patients with melanoma, medical professional should not resort to dose lowering. She also adds that finding reliable molecular targets in older patients.
Response Time and BRAF Status Factor Into IO Selection for Melanoma
January 29th 2025During a Case-Based Roundtable® event, Thach-Giao Truong, MD, discussed how data from the CheckMate-067 and RELATIVITY-047 affect their choice of therapy for metastatic melanoma in the first article of a 2-part series.
Read More
